Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 25;11:597703. doi: 10.3389/fphar.2020.597703

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Huang, Liu, Hsu, Yang, Lee, Huang and Wu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Trajectory plots for the percentage of relative change in HbA1c (A) and FPG (B) in the high-dose and low-dose RCEG group. Data points presented in aquamarine belong to the high-dose group, and those in orange refer to the low-dose group. Each dashed and solid thin line represents the time-course of HbA1c and FPG changes for a patient in the high-dose and low-dose RCEG group, respectively. A multivariate nonlinear mixed-effects model was applied to acquire the dashed and solid thick lines, exhibiting the fitted mean profiles of patients treated with high-dose and low-dose RCEG, respectively. (A) The mean percentage change in HbA1c from baseline at 12, 24, 36, and 48 weeks in the high- and low-dose groups. (B) Relative changes in mean FPG at the same time points in both groups. FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; RCEG, Rhizoma Coptidis extract granules.